Skip to main content
×
×
Home

Polypharmacy and high-dose antipsychotic regimes in the community

  • Tongeji E. Tungaraza (a1), Seema Gupta (a2), Jane Jones (a2), Rob Poole (a3) and Gary Slegg (a4)...
Abstract
Aims and method

To determine the pattern of psychotropic prescribing in a group of people with psychosis who were living in the community under community mental health team (CMHT) care. Case-note entries over the previous 12 months were examined.

Results

Only a third of individuals were on one psychotropic medication. Atypical antipsychotics were prescribed to 80.6%. Polypharmacy was common. A third of people were taking three or more psychotropic drugs and 13.7% were on high-dose regimes, mostly involving two atypical antipsychotics.

Clinical implications

The use of atypicals has not eliminated polypharmacy or high-dose antipsychotic regimes. Clinicians need to be aware of this long-standing problem.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Polypharmacy and high-dose antipsychotic regimes in the community
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Polypharmacy and high-dose antipsychotic regimes in the community
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Polypharmacy and high-dose antipsychotic regimes in the community
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Tongeji E. Tungaraza (eliphaz@doctors.org.uk)
Footnotes
Hide All

See editorial, pp. 41–43, and review article, pp. 58–62, this issue.

Declaration of interest

T.E.T. accepted sponsorship to attend conferences from Janssen-Cilag, Eli Lilly, Bristol-Myers Squibb and Otsuka Pharmaceuticals. R.P. has accepted speakers' fees from Lundbeck, Eli Lilly and Pfizer, and accepted sponsorship to attend conferences from Wyeth, AstraZeneca and Eli Lilly.

Footnotes
References
Hide All
1 Stahl, SM. Antipsychotic polypharmacy. Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60: 425–6.
2 Canales, PL, Olsen, J, Miller, AL, Crismon, ML. The role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12: 179–88.
3 Lelliott, P, Paton, C, Harrington, M, Konsolaki, M, Sensky, T, Okocha, C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 2002; 26: 411–4.
4 Ito, H, Koyama, A, Higuchi, T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243–7.
5 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE, 2002.
6 Royal College of Psychiatrists. Consensus Statement on High Dose Antipsychotic Medication (Council Report CR138). Royal College of Psychiatrists, 2006.
7 Barbui, C, Nosè, M, Mazzi, MA, Thornicroft, G, Schene, A, Becker, T, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Pharmacol 2006; 21: 355–62.
8 Jensen, B. Antipsychotic comparison chart. RxFiles, 2003 (http://meds.queensu.ca/~clpsych/orientation/Antipschotics%20Comparison%20Chart.pdf).
9 Taylor, D, Paton, C, Kerwin, R. The Maudsley Prescribing Guidelines (8th edn). Taylor & Francis, 2006.
10 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
11 Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.
12 Centorrino, F, Eakin, M, Bahk, W, Kelleher, JP, Goren, J, Salvatore, P, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002; 159: 1932–5.
13 Freudenreich, O, Goff, DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323–30.
14 Tapp, A, Wood, AE, Secrest, L, Erdmann, J, Cubberley, L, Kilzieh, N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55–9.
15 Sernyak, MJ, Rosenheck, R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004; 65: 15971600.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 7 *
Loading metrics...

Abstract views

Total abstract views: 26 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 22nd April 2018. This data will be updated every 24 hours.

Polypharmacy and high-dose antipsychotic regimes in the community

  • Tongeji E. Tungaraza (a1), Seema Gupta (a2), Jane Jones (a2), Rob Poole (a3) and Gary Slegg (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *